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Abstract 
Purpose: Methadone maintenance treatment is a life-saving treatment for people with opioid use disorders 
(OUD). The coronavirus pandemic (COVID-19) introduces many concerns surrounding access to opioid 
treatment. In March 2020, the Substance Abuse and Mental Health Services Administration (SAMHSA) 
issued guidance allowing the expansion of take-home methadone doses. We sought to describe changes to 
treatment experiences from the perspective of persons receiving methadone at outpatient treatment 
facilities for OUD. 
Methods: We conducted an in-person survey among 104 persons receiving methadone from three clinics 
in central North Carolina. Surveys collected information on demographic characteristics, methadone 
treatment history, and experiences with take-home methadone doses in the context of COVID-19 (i.e., 
before and since March 2020).  
Results: Before COVID-19, the clinic-level percent of participants receiving any amount of days’ supply 
of take-home doses at each clinic varied ranged from 56% to 82%, while it ranged from 78% to 100% 
since COVID-19. The clinic-level percent of participants receiving a take-homes days’ supply of a week 
or longer (i.e., ≥6 days) since COVID-19 ranged from 11% to 56%. Of the 87 participants who received 
take-homes since COVID-19 began, only four reported selling their take-home doses.  
Conclusions: Our study found variation in experiences of take-home dosing by clinic and little diversion 
of take-home doses. While SAMSHA guidance should allow expanded access to take-home doses, 
adoption of these guidelines may vary at the clinic level. The adoption of these policies should be 
explored further, particularly in the context of benefits to patients seeking treatment for OUD.  
 




















Methadone maintenance treatment is a life-saving treatment for people with opioid use disorder 
(OUD) (Mattick et al., 2009; Woody et al., 2007). However, the strict requirements of daily in-person, 
supervised dosing are often burdensome and time-consuming for people participating in treatment 
(Kourounis et al., 2016). Historically, people receiving methadone are sometimes given take-home doses, 
however, these doses may be limited to patients with long-term treatment histories and may be provided 
in doses lasting only one or two days at a time (Walley et al., 2012).  
The coronavirus pandemic (COVID-19) has created an urgency for opioid treatment programs 
(OTPs) to respond by ensuring continued access for existing patients, promoting patient safety, and 
expanding to new patients (Davis & Samuels, 2020; Del Pozo et al., 2020; Khatri & Perrone, 2020; 
Krawczyk et al., 2020; Leppla & Gross, 2020). In March 2020, the Substance Abuse and Mental Health 
Services Administration (SAMHSA) issued guidelines allowing expanded use of take-home doses for 
more “stable” patients, likely relevant to those who have displayed longer durations of treatment 
(Substance Abuse and Mental Health Services Administration, 2020).  
In an effort to examine changes to methadone take-home policies in the early months of COVID-
19, we sought to capture experiences of persons receiving methadone at several methadone clinics in 
central North Carolina.  
2. Methods 
We conducted a survey among persons receiving methadone prescriptions at methadone clinics in 
central North Carolina on Monday mornings during June and July 2020. We identified all methadone 
clinics within a 50-mile radius of Greensboro, North Carolina (n=10) and contacted them in a randomized 
order. The first three that agreed to participate were included in the study. Two clinics were for-profit and 
one was non-profit. Sample size estimations suggested that we would need approximately 100 patients to 
have a meaningful sample. The survey was developed by the authors and reviewed by persons with lived 
experience of methadone treatment. The survey was also reviewed by clinic staff, but no changes were 
made upon this review. 
On-site recruitment and survey administration was conducted by staff from the North Carolina 
Survivors Union (NCSU). NCSU is a self-support group of people with lived experience of drug use that 
operates a drop-in center and harm reduction program in Greensboro, North Carolina. NCSU 
representatives approached persons entering the clinic and administered verbal consent to those indicating 
interest in survey participation. Among the three clinics included in our survey, the percent of persons 
approached who participated were 79% from Clinic A, 34% from Clinic B, and 54% from Clinic C. 
Among persons who provided verbal consent, we administered a one-page paper-based questionnaire 
asking about participants’ demographic characteristics, methadone treatment history, receipt of and 
experiences with take-home doses, and knowledge of peer’s experiences with take-home doses.  
We examined participants’ self-reported experiences before and since COVID-19, which was 
defined in both the survey and analysis as before and after March 1, 2020. We examined frequencies and 
percentages of participants’ reported specific characteristics. All analyses were performed using SAS 9.4.  
This study was reviewed and approved by the University of North Carolina at Chapel Hill Institutional 
Review Board. People with lived experience were involved in design of the study, questionnaire 
development, data collection, and interpretation of data. 
3. Results 
3.1. Characteristics of Survey Participants 
Among 104 survey participants recruited from three methadone clinics in central North Carolina, 
54.5% were aged 18-34 years old, 55.9% were male, and 88.2% were non-Hispanic White (Table 1). 
Approximately 18.1% (n=17) of participants had been receiving methadone in their current treatment 
episode for less than six months, 27.7% (n=26) had been receiving methadone for six to 12 months, and 
54.3% (n=51) had been receiving methadone for more than 12 months. When participants receiving take-
home doses were asked about the length of their usual days’ supply, 59.8% (n=52) reported their usual 
days’ supply was for 1-2 days, 13.8% (n=12) reported 4-5 days, 17.2% (n=15) reported 6-12 days, and 
9.2% (n=8) reported more than 12 days. 
3.2. Reported Take-Home Dosing Experiences 
Among all participants, 68.3% (n=69) had received take-home doses at any point prior to the 
beginning of COVID-19-related responses (i.e., before March 2020). This proportion increased to 91.6% 
(n=87) receiving take-home doses since the widespread onset of COVID-19. Only six (6.9%) of the 87 
participants receiving take-home doses since COVID-19 reported either selling or sharing their doses. 
Specifically, four persons (4.6%) reported selling their doses and three (3.4%) reported sharing their 
doses. Among participants receiving take-homes doses, 71.3% (n=62) reported storing doses in a child-
resistant or locked container, 64.4% (n=56) reported having a safe storage location at home, while only 
3.4% (n=3) reported that other people residing at their home could access their doses. Among all 
participants, regardless of whether they received take-home doses, 14.4% (n=15) reported knowing 
someone who gave away doses to help someone else. Only five (4.8%) participants reported knowing 
someone who had other people they lived with get into their doses. The most reported hypothetical 
reasons for giving away doses included: needing money or drugs (38.5%), helping someone else like a 
friend (37.5%), and saving up for travel (28.8%).  
3.3. Variation in Take-Home Dosing by Clinic and Treatment Duration 
The percent of participants receiving take-home doses before COVID-19 ranged from 56.1% in 
Clinic C to 82.1% in Clinic A (Figure 1a). Participants receiving any take-home doses since COVID-19 
varied from 92.6% in Clinic A, 100% in Clinic B, and 78.0% in Clinic C. Participants receiving take-
homes of a week supply or longer (six or more days) since COVID-19 varied from 55.6% in Clinic A, 
13.3% in Clinic B, and 10.5% in Clinic C. While two-thirds of participants with treatment durations 
longer than 12 months received take-homes prior to COVID-19, 56.3% of participants with treatment 
duration less than six months received any amount of take-homes prior to COVID-19 (Figure 1b).  
4. Discussion 
Our study found variation in the proportion of persons receiving take-home doses since COVID-
19 at several clinics in central North Carolina. While our study is specific to methadone maintenance 
treatment in three clinics, these results may suggest a need for a better understanding of how the 
SAMHSA directive was implemented during COVID-19. The COVID-19 pandemic creates substantial 
urgency in improving and expanding access to persons seeking OUD treatment (Davis & Samuels, 2020; 
Peavy et al., 2020). In addition, COVID-19 presents an opportunity to re-examine dated regulations 
surrounding OUD treatment (del Pozo & Beletsky, 2020; Krawczyk et al., 2020).  
Given the SAMSHA guidelines allowing expanded access to take-home doses (Substance Abuse 
and Mental Health Services Administration, 2020), we expected to identify less variation in take-home 
practices by clinic. In fact, some survey participants reported preferring when the clinic provided take-
home doses every other day, indicating that some clinics may have provided take-home doses at one point 
but stopped by the time the survey was administered in June and July 2020. Very few participants 
reported selling or giving away their take-home doses. Conversations surrounding diversion have 
historically focused on persons selling their methadone doses (Institute of Medicine (US) Committee on 
Federal Regulation of Methadone Treatment, 1995). However, our survey suggests selling doses may be 
relatively uncommon. In addition, reasons for giving away or otherwise not taking methadone take-homes 
as prescribed may follow a much more innocuous narrative than diversion for profit, such as saving up 
doses for travel or helping someone else. A continuous focus on diversion as a central rationale for 
restricting take-home dosing may increase stigma and further marginalize people who are prescribed 
methadone for OUD treatment. Instead, our results suggest the need to examine the benefits of receiving 
take-home doses on treatment, recovery, and general well-being of person receiving methadone. 
Our study has several limitations. First, due to our study being administered on a single day per 
clinic, we did not capture true prevalence of take-home doses overall among survey participants. Rather, 
these results can be used to assess variation in persons receiving take-home doses by clinic and treatment 
duration. Second, participation in the survey varied by clinic. We believe this was due to some 
participants being more strongly encouraged to participate by clinic staff. Finally, it is possible social 
desirability bias was present in the self-report of sensitive questions, such as those related to diversion or 
safe storage procedures. Although the survey was anonymized, this concern may be a factor if 
participants were worried about repercussions leading to disruptions in their treatment. However, our 
survey was administered by a separate organization (NCSU) comprised of persons with lived experience 
of drug use and community advocates, which may result in participants being be more comfortable 
disclosing sensitive behaviors to this group rather than clinic staff. 
5. Conclusions 
Our findings have implications for evaluations of the SAMHSA pandemic directive. We observed 
considerable heterogeneity in take-home practices between clinics, suggesting differences in 
interpretation. OTPs should reduce barriers to treatment during COVID-19 and consider expanding access 
to take-home doses while providing harm reduction messaging to their patients. Instituting additional 
barriers to treatment may come at the cost of lives; therefore, we should make treatment more accessible, 
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Table 1. Summary of survey self-reported participant demographic characteristics and methadone take-
home dosing experiences among participants of three clinics in central North Carolina (N=104). 
  N=104 % 
Age   
18-34 54 54.5% 
35-54 41 41.4% 
55+ 4 4.0% 
Missing 5  
Gender   
Female 45 44.1% 
Male 57 55.9% 
Missing 2  
Race/ethnicity   
Hispanic/Latino 1 1.0% 
Non-Hispanic Black 8 7.8% 
Non-Hispanic White 90 88.2% 
Other 3 2.9% 
Missing 2  
Duration of methadone treatment in current treatment episode   
<6 months 17 18.1% 
6 months – 12 months 26 27.7% 
>12 months 51 54.3% 
Missing 10  
Personally knew of anyone who:   
Gave take-home doses to help someone else 15 14.4% 
Lost or had take-homes doses stolen 7 6.7% 
Had people they live with access their take-home doses 5 4.8% 
Skipped take-home doses to save up for later personal use 11 10.6% 
Hypothetical reasons why people might give away take-home doses:   
Saving up for when clinic is closed 22 21.2% 
Saving up for travel 30 28.8% 
Helping someone else 39 37.5% 
Needing money or drugs 40 38.5% 
Received take-home doses before COVID-19 69 68.3% 
Received take-home doses since COVID-19 87 91.6% 
Before COVID-19 was defined as prior to March 2020. Since COVID-19 was defined as since March 
2020. Length of take-home doses was defined by asking participants the typical days’ supply of take-
home doses they received since March 2020. Duration of treatment was identified by asking participants 




Figure 1. Percent of survey participants take-home dose experiences pre- and post-COVID-19 by clinic 
and treatment duration.  
a) Take-home doses by clinic 
 
b) Take-home doses by methadone prescription duration 
 
Before COVID-19 was defined as prior to March 2020. Since COVID-19 was defined as since March 
2020. Length of take-home doses was defined by asking participants the typical days’ supply of take-
home doses they received since March 2020. Duration of treatment was identified by asking participants 
about the length of methadone treatment in their current treatment episode. In Figure 1a, data were 
unavailable for: 4 of the 31 participants at Clinic A, 2 of the 32 participants at Clinic B, and 3 of the 41 
participants at Clinic C. In Figure 1b, data were unavailable for: 5 of the 17 participants in the <6 month 
category for take-homes since COVID-19, 0 of the 26 participants in the 6-12 month category for take-














































































Before COVID-19 (any amount) Since COVID-19 (any amount) Since COVID-19 (week supply or longer)
